Trials / Completed
CompletedNCT04392271
A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to about 10 weeks. Screening must be completed within four weeks prior to enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3372689 | Administered orally. |
| DIAGNOSTIC_TEST | [18F]LSN3316612 | Administered intravenously (IV). |
Timeline
- Start date
- 2020-08-06
- Primary completion
- 2020-10-14
- Completion
- 2020-10-14
- First posted
- 2020-05-18
- Last updated
- 2020-11-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04392271. Inclusion in this directory is not an endorsement.